Reirradiation of recurrent meningioma

Andrzej P. Wojcieszynski, Nitin Ohri, David W. Andrews, James J. Evans, Adam P. Dicker, Maria Werner-Wasik

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Management of meningioma includes observation, resection, and radiation therapy (RT). For patients with recurrent disease, similar options exist. However, the control rate following a second course of RT for recurrent disease is unknown. We reviewed an institutional database of patients with meningioma treated with stereotactic radiosurgery or fractionated stereotactic RT who underwent a second course for recurrent disease. Cox regression model was used for analysis. Variables tested included tumor volume, RT type, tumor grade, age at diagnosis, time to progression, and interval between RT. Eleven of 19 patients (58%) experienced disease progression. Median time to second progression was 10 months. Freedom from progression at one year was lower in patients with grade II or III tumors compared to those with grade 1 or unknown histology (17% compared to 92%, p = 0.0054). Cox regression showed that a grade II-III tumor affects progression-free survival (PFS), with a hazard ratio of 5.37 (p = 0.011). Median time to progression (MTP) for patients with grade II-III tumors was eight months. MTP was not reached for patients with grade 1/unknown tumors. Reirradiation for recurrent meningioma yields modest tumor control rates but for patients with grade II or III tumors, outcomes are poor.

Original languageEnglish (US)
Pages (from-to)1261-1264
Number of pages4
JournalJournal of Clinical Neuroscience
Volume19
Issue number9
DOIs
StatePublished - Sep 2012
Externally publishedYes

Fingerprint

Meningioma
Radiotherapy
Neoplasms
Radiosurgery
Re-Irradiation
Tumor Burden
Proportional Hazards Models
Disease-Free Survival
Disease Progression
Histology
Observation
Databases

Keywords

  • Meningioma
  • Radiation therapy
  • Radiosurgery
  • Recurrent
  • Tumor

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Physiology (medical)

Cite this

Wojcieszynski, A. P., Ohri, N., Andrews, D. W., Evans, J. J., Dicker, A. P., & Werner-Wasik, M. (2012). Reirradiation of recurrent meningioma. Journal of Clinical Neuroscience, 19(9), 1261-1264. https://doi.org/10.1016/j.jocn.2012.01.023

Reirradiation of recurrent meningioma. / Wojcieszynski, Andrzej P.; Ohri, Nitin; Andrews, David W.; Evans, James J.; Dicker, Adam P.; Werner-Wasik, Maria.

In: Journal of Clinical Neuroscience, Vol. 19, No. 9, 09.2012, p. 1261-1264.

Research output: Contribution to journalArticle

Wojcieszynski, AP, Ohri, N, Andrews, DW, Evans, JJ, Dicker, AP & Werner-Wasik, M 2012, 'Reirradiation of recurrent meningioma', Journal of Clinical Neuroscience, vol. 19, no. 9, pp. 1261-1264. https://doi.org/10.1016/j.jocn.2012.01.023
Wojcieszynski AP, Ohri N, Andrews DW, Evans JJ, Dicker AP, Werner-Wasik M. Reirradiation of recurrent meningioma. Journal of Clinical Neuroscience. 2012 Sep;19(9):1261-1264. https://doi.org/10.1016/j.jocn.2012.01.023
Wojcieszynski, Andrzej P. ; Ohri, Nitin ; Andrews, David W. ; Evans, James J. ; Dicker, Adam P. ; Werner-Wasik, Maria. / Reirradiation of recurrent meningioma. In: Journal of Clinical Neuroscience. 2012 ; Vol. 19, No. 9. pp. 1261-1264.
@article{79390caac8404f1bb39069e95c99d2d9,
title = "Reirradiation of recurrent meningioma",
abstract = "Management of meningioma includes observation, resection, and radiation therapy (RT). For patients with recurrent disease, similar options exist. However, the control rate following a second course of RT for recurrent disease is unknown. We reviewed an institutional database of patients with meningioma treated with stereotactic radiosurgery or fractionated stereotactic RT who underwent a second course for recurrent disease. Cox regression model was used for analysis. Variables tested included tumor volume, RT type, tumor grade, age at diagnosis, time to progression, and interval between RT. Eleven of 19 patients (58{\%}) experienced disease progression. Median time to second progression was 10 months. Freedom from progression at one year was lower in patients with grade II or III tumors compared to those with grade 1 or unknown histology (17{\%} compared to 92{\%}, p = 0.0054). Cox regression showed that a grade II-III tumor affects progression-free survival (PFS), with a hazard ratio of 5.37 (p = 0.011). Median time to progression (MTP) for patients with grade II-III tumors was eight months. MTP was not reached for patients with grade 1/unknown tumors. Reirradiation for recurrent meningioma yields modest tumor control rates but for patients with grade II or III tumors, outcomes are poor.",
keywords = "Meningioma, Radiation therapy, Radiosurgery, Recurrent, Tumor",
author = "Wojcieszynski, {Andrzej P.} and Nitin Ohri and Andrews, {David W.} and Evans, {James J.} and Dicker, {Adam P.} and Maria Werner-Wasik",
year = "2012",
month = "9",
doi = "10.1016/j.jocn.2012.01.023",
language = "English (US)",
volume = "19",
pages = "1261--1264",
journal = "Journal of Clinical Neuroscience",
issn = "0967-5868",
publisher = "Churchill Livingstone",
number = "9",

}

TY - JOUR

T1 - Reirradiation of recurrent meningioma

AU - Wojcieszynski, Andrzej P.

AU - Ohri, Nitin

AU - Andrews, David W.

AU - Evans, James J.

AU - Dicker, Adam P.

AU - Werner-Wasik, Maria

PY - 2012/9

Y1 - 2012/9

N2 - Management of meningioma includes observation, resection, and radiation therapy (RT). For patients with recurrent disease, similar options exist. However, the control rate following a second course of RT for recurrent disease is unknown. We reviewed an institutional database of patients with meningioma treated with stereotactic radiosurgery or fractionated stereotactic RT who underwent a second course for recurrent disease. Cox regression model was used for analysis. Variables tested included tumor volume, RT type, tumor grade, age at diagnosis, time to progression, and interval between RT. Eleven of 19 patients (58%) experienced disease progression. Median time to second progression was 10 months. Freedom from progression at one year was lower in patients with grade II or III tumors compared to those with grade 1 or unknown histology (17% compared to 92%, p = 0.0054). Cox regression showed that a grade II-III tumor affects progression-free survival (PFS), with a hazard ratio of 5.37 (p = 0.011). Median time to progression (MTP) for patients with grade II-III tumors was eight months. MTP was not reached for patients with grade 1/unknown tumors. Reirradiation for recurrent meningioma yields modest tumor control rates but for patients with grade II or III tumors, outcomes are poor.

AB - Management of meningioma includes observation, resection, and radiation therapy (RT). For patients with recurrent disease, similar options exist. However, the control rate following a second course of RT for recurrent disease is unknown. We reviewed an institutional database of patients with meningioma treated with stereotactic radiosurgery or fractionated stereotactic RT who underwent a second course for recurrent disease. Cox regression model was used for analysis. Variables tested included tumor volume, RT type, tumor grade, age at diagnosis, time to progression, and interval between RT. Eleven of 19 patients (58%) experienced disease progression. Median time to second progression was 10 months. Freedom from progression at one year was lower in patients with grade II or III tumors compared to those with grade 1 or unknown histology (17% compared to 92%, p = 0.0054). Cox regression showed that a grade II-III tumor affects progression-free survival (PFS), with a hazard ratio of 5.37 (p = 0.011). Median time to progression (MTP) for patients with grade II-III tumors was eight months. MTP was not reached for patients with grade 1/unknown tumors. Reirradiation for recurrent meningioma yields modest tumor control rates but for patients with grade II or III tumors, outcomes are poor.

KW - Meningioma

KW - Radiation therapy

KW - Radiosurgery

KW - Recurrent

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=84865034845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865034845&partnerID=8YFLogxK

U2 - 10.1016/j.jocn.2012.01.023

DO - 10.1016/j.jocn.2012.01.023

M3 - Article

VL - 19

SP - 1261

EP - 1264

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

SN - 0967-5868

IS - 9

ER -